Novavax Shares Surge 20% After Rival's Strong Trial Data Boosts Vaccine Stocks
Novavax Inc. (NVAX) shares experienced their best trading session since January, jumping 20% on Monday. This surge was attributed to a competitor's positive late-stage trial results for a vaccine, which broadly lifted vaccine stocks. Moderna shares also rose approximately 7%.